Cardiac Biomarkers Associated With CV Outcomes Among Patients With PsD

According to a study published in Arthritis & Rheumatology, the cardiac biomarkers troponin I (cTnl) and N-terminal pro-brain-type natriuretic peptide (NT-proBNP) are associated with cardiovascular (CV) outcomes in patients with psoriatic disease (PsD).

Researchers determined the association of cTnl and NT-proBNP with carotid plaque burden and CV outcomes independent of the Framingham Risk Score (FRS) in 1000 patients with PsD. In a longitudinal cohort study, investigators measured carotid total plaque area (TPA) in 358 participants at baseline and cTnl and NT-proBNP were measured with automated clinical assays.

cTnl and NT-proBNP were both associated with TPA in univariate analyses, but after adjusting for CV risk factors, the association was only significant for cTnl (adjusted β coefficient 0.21 [95% CI 0, 0.41], P = .047). A total of 64 patients had incident CV events. No improvement in predictive performance was determined when comparing FRS alone with FRS plus cardiac biomarkers.

“In patients with PsD, cTnI may reflect the burden of atherosclerosis, independent of traditional CV risk factors. cTnI and NT-proBNP are associated with incident CV events independent of the FRS, however, further study of their role in CV risk stratification is warranted,” concluded the study authors.

Reference
Colaço K, Lee KA, Akhtari S, et al. Association of cardiac biomarkers with cardiovascular outcomes in patients with psoriatic arthritis and psoriasis: a longitudinal cohort study. Arthritis Rheumatol. 2022;10.1002/art.42079. doi:10.1002/art.42079